GFR斜率作为临床试验肾脏病进展替代终点的荟萃分析
该荟萃分析纳入47项RCT、60,620例受试者,评估GFR斜率作为CKD进展替代终点的表现。贝叶斯混合效应分析显示,3年总斜率与慢性斜率的治疗效应可准确预测临床终点效应(R²中位数分别为0.97和0.96)。在足够样本量下,总斜率或慢性斜率治疗效应≥0.75 ml/min/1.73 m²/yr可预测临床获益,概率至少96%。
要点
- 3年总GFR斜率治疗效应可准确预测临床终点效应(R²=0.97)。
- 慢性斜率治疗效应同样准确预测临床终点(R²=0.96)。
- 足够样本量下,斜率效应≥0.75 ml/min/1.73 m²/yr可预测临床获益。
核心结论
- 在足够大的样本量下,GFR斜率可能作为CKD随机对照试验临床终点的可行替代终点。
研究设计与样本
- 研究为荟萃分析,纳入47项随机对照试验,涉及12种干预措施和60,620例受试者。
- 采用贝叶斯混合效应分析评估GFR斜率治疗效应与临床终点的关联。
主要发现
- 3年总GFR斜率治疗效应准确预测临床终点效应,中位R²=0.97(95% BCI 0.78至1.00)。
- 慢性斜率治疗效应准确预测临床终点效应,R²=0.96(95% BCI 0.63至1.00)。
- 足够样本量下,总斜率或慢性斜率治疗效应≥0.75 ml/min/1.73 m²/yr预测临床获益概率至少96%。
临床怎么用
- 在CKD随机对照试验中,可考虑将GFR斜率作为替代终点以评估早期治疗效应。
- 应用GFR斜率替代终点时需确保足够样本量,并以3年总斜率或慢性斜率效应≥0.75 ml/min/1.73 m²/yr作为预测临床获益的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have not approved using differences in the change in GFR from the beginning to the end of a randomized, controlled trial as an end point in CKD because it is not clear whether small changes in the GFR slope will translate to clinical benefits. METHODS: To assess the use of GFR slope as a surrogate end point for CKD progression, we performed a meta-analysis of 47 RCTs that tested 12 interventions in 60,620 subjects. We estimated treatment effects on GFR slope (mean difference in GFR slope between the randomized groups), for the total slope starting at baseline, chronic slope starting at 3 months after randomization, and on the clinical end point (doubling of serum creatinine, GFR<15 ml/min per 1.73 m2, or ESKD) for each study. We used Bayesian mixed-effects analyses to describe the association of treatment effects on GFR slope with the clinical end point and to test how well the GFR slope predicts a treatment's effect on the clinical end point. RESULTS: Across all studies, the treatment effect on 3-year total GFR slope (median R2=0.97; 95% Bayesian credible interval [BCI], 0.78 to 1.00) and on the chronic slope (R2 0.96; 95% BCI, 0.63 to 1.00) accurately predicted treatment effects on the clinical end point. With a sufficient sample size, a treatment effect of 0.75 ml/min per 1.73 m2/yr or greater on total slope over 3 years or chronic slope predicts a clinical benefit on CKD progress with at least 96% probability. CONCLUSIONS: With large enough sample sizes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.
引用
- Inker LA, Heerspink HJL, Tighiouart H, et al. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. 2019. PMID: 31292197. doi:10.1681/ASN.2019010007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。